Abstract

The meso-diencephalic dopaminergic (mdDA) neurons regulate various critical processes in the mammalian nervous system, including voluntary movement and a wide range of behaviors such as mood, reward, addiction, and stress. mdDA neuronal loss is linked with one of the most prominent human movement neurological disorders, Parkinson’s disease (PD). How these cells die and regenerate are two of the most hotly debated PD research topics. As for the latter, it has been long known that a series of transcription factors (TFs) involves the development of mdDA neurons, specifying cell types and controlling developmental patterns. In vitro and in vivo, TFs regulate the expression of tyrosine hydroxylase, a dopamine transporter, vesicular monoamine transporter 2, and L-aromatic amino acid decarboxylase, all of which are critical for dopamine synthesis and transport in dopaminergic neurons (DA neurons). In this review, we encapsulate the molecular mechanism of TFs underlying embryonic growth and maturation of mdDA neurons and update achievements on dopaminergic cell therapy dependent on knowledge of TFs in mdDA neuronal development. We believe that a deeper understanding of the extrinsic and intrinsic factors that influence DA neurons’ fate and development in the midbrain could lead to a better strategy for PD cell therapy.

Highlights

  • The meso-diencephalic dopaminergic neurons are the primary dopamine (DA) sources in the mammalian central nervous system [1]

  • The differentiation and maturation of meso-diencephalic dopaminergic (mdDA) neurons are accompanied by their migration. mdDA neurons migrate away from the floor plate (FP) of the ventral mesencephalon, called the ventricular zone (VZ), into the mantle layer and form three different mdDA neuron clusters: substantia nigra pars compacta (SNpc) (A9) on the lateral side, ventral tegmental area (VTA) (A10) on the medial side, and the posterior retro-rubral field (RRF; A8) [37]

  • Mature DA neurons were generated from induced neural progenitor cells (iNPCs) forced expression of Nuclear receptor-related factor1 (Nurr1) and Forkhead box A2 (Foxa2), but the neuronal maturity of engrafted neurons was different between in vivo and in vitro when the iNPCs were transplanted into the striatum of Parkinson’s disease (PD) rats [95], which may result from poor graft quality, immune response or poor host microenvironment

Read more

Summary

Introduction

The meso-diencephalic dopaminergic (mdDA) neurons are the primary dopamine (DA) sources in the mammalian central nervous system [1]. Deep brain stimulation is applied for patients who experience a prominent tremor or uncontrolled motor fluctuations [10] These treatments can only alleviate the physical symptoms rather than prevent or delay the disease progression [11]. Ngn, and NeuroD1 are neural progenitor cell markers, whereas Pitx and Nurr are mdDA neuron-specific markers. These TFs have long been known to involve the differentiation, maturation, and maintenance of mdDA [15–17]. We first seek to encapsulate the mechanism discovered to be underlying mdDA neuronal development via the TFs and focus on the application of this updated knowledge in stem cell therapy, i.e., how to promote the differentiation of stem cells into dopaminergic neurons (DA neurons) in vitro or in vivo and even within the therapeutic target. This section will go over the principles of mdDA neurodevelopment and elucidate the TFs’ roles in promoting mdDA neurodifferentiation

Induction of Midbrain FP
Development
Differentiation and Maturation
Migration
Dopamine Cell Therapy
Major Findings
Combinations of TFs
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call